Skip to main content
Premium Trial:

Request an Annual Quote

SIRS-Lab Declares Insolvency, Seeks Investor to Commercialize Sepsis Test

NEW YORK (GenomeWeb News) – SIRS-Lab, a German molecular diagnostic developer, said today that it has begun insolvency proceedings and it is seeking an investor to commercialize its leading product, a test for the causative agent of sepsis.

The company embarked on a clinical trial of Vyoo, its PCR- and array-based sepsis test, in 2011, and said this week that it completed the trial at the end of last year.

The trial enrolled 1,000 patients at 13 centers across Germany. The company said its technology can determine what pathogens are present in a sample and what antibiotic resistance they harbor within seven hours, allowing clinicians to begin therapies faster than with standard diagnostic methods.

But to bring the test to market, the company said it needs further investment.

The District Court of Gera in Germany has appointed Rolf Rattunde of Leonhardt Rechtsanwälte Erfurt as the company's provisional insolvency administrator.

"In order to bring the test to market, further investments are necessary upon which the current shareholders cannot agree," Rattunde said in a statement. "Therefore, we are now searching for investors for this very interesting diagnostics company. The first meetings with management and employees made me very confident to proceed with operations."

SIRS-Lab has 30 employees.